Table 1.
Characteristics of the primary pelvic cancer (PPC) patients.
| Total N = 574,253 |
NRT N = 432,422 |
RT N = 141,831 |
RT Type | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| EBRT n = 104,194 |
EBRT–BRT n = 37,637 |
|||||||||
| n a | n (%) or mean ± SD | n a | n (%) or mean ± SD | n a | n (%) or mean ± SD | n a | n (%) or mean ± SD | n a | n (%) or mean ± SD | |
| Age at diagnosis | 573,306 | 65.00 ± 12.36 |
432,081 | 64.67 ± 12.75 |
141,225 | 66.02 ± 11.04 |
103,947 | 66.02 ± 11.04 |
37,278 | 62.02 ± 12.11 |
| ≤60 | 191,026 (33.32) | 152,976 (35.40) | 38,050 (26.94) | 23,165 (22.29) | 14,885 (39.93) | |||||
| >60 | 382,280 (66.68) | 279,105 (64.60) | 103,175 (73.06) | 80,782 (77.71) | 22,393 (60.07) | |||||
| Gender | 573,306 | 432,081 | 141,225 | 103,947 | 37,278 | |||||
| Male | 395,647 (69.01) | 297,433 (68.84) | 98,214 (69.54) | 79,563 (76.54) | 18,651 (50.03) | |||||
| Female | 177,659 (30.99) | 134,648 (31.16) | 43,011 (30.46) | 24,384 (23.46) | 18,627 (49.97) | |||||
| Race | 573,306 | 432,081 | 141,225 | 103,947 | 37,278 | |||||
| White | 479,744 (83.68) | 369,500 (85.52) | 110,244 (78.06) | 81,755 (78.65) | 28,489 (76.42) | |||||
| Black | 57,981 (10.11) | 37,817 (8.75) | 20,164 (14.28) | 14,296 (13.75) | 5,868 (15.74) | |||||
| Other | 35,581 (6.21) | 24,764 (5.73) | 10,817 (7.66) | 7,896 (7.60) | 2,921 (7.84) | |||||
| SPC | 573,306 | 432,081 | 141,225 | 103,947 | 37,278 | |||||
| Yes | 91,359 (15.94) | 69,253 (16.03) | 22,106 (15.65) | 16,366 (15.74) | 5,740 (15.40) | |||||
| No | 481,947 (84.06) | 362,828 (83.97) | 119,119 (84.35) | 87,581 (84.26) | 31,538 (84.60) | |||||
| SPRC | 573,306 | 432,081 | 141,225 | 103,947 | 37,278 | |||||
| Yes | 1,491 (0.26) | 979 (0.23) | 512 (0.36) | 325 (0.31) | 187 (0.50) | |||||
| No | 571,815 (99.74) | 431,102 (99.77) | 140,713 (99.64) | 103,622 (99.69) | 37,091 (99.50) | |||||
| Site | 573,306 | 432,081 | 141,225 | 103,947 | 37,278 | |||||
| Cervix | 33,428 (5.83) | 17,003 (3.94) | 16,425 (11.63) | 5,930 (5.70) | 10,495 (28.15) | |||||
| Corpus uteri | 93,201 (16.26) | 69,980 (16.20) | 23,221 (16.44) | 15,128 (14.55) | 8,093 (21.71) | |||||
| Ovary | 16,680 (2.91) | 15,861 (3.67) | 819 (0.58) | 795 (0.76) | 24 (0.06) | |||||
| Prostate | 291,395 (50.83) | 199,655 (46.21) | 91,740 (64.96) | 73,106 (70.33) | 18,634 (49.99) | |||||
| Bladder | 138,602 (24.18) | 129,582 (29.99) | 9,020 (6.39) | 8,988 (8.65) | 32 (0.09) | |||||
| Grade | 516,100 | 386,043 | 130,057 | 97,798 | 32,259 | |||||
| I~II | 315,974 (61.22) | 249,194 (64.55) | 66,780 (51.35) | 49,537 (50.65) | 17,243 (53.45) | |||||
| III~IV | 200,126 (38.78) | 136,849 (35.45) | 63,277 (48.65) | 48,261 (49.35) | 15,016 (46.55) | |||||
| Stage | 573,306 | 432,081 | 141,225 | 103,947 | 37,278 | |||||
| Localized | 221,450 (38.63) | 198,864 (46.02) | 22,586 (15.99) | 14,717 (14.16) | 7,869 (21.11) | |||||
| Regional | 60,461 (10.55) | 33,562 (7.77) | 26,899 (19.05) | 16,124 (15.51) | 10,775 (28.90) | |||||
| Localized/regional (prostate-related cases) | 291,395 (50.83) | 199,655 (46.21) | 91,740 (64.96) | 73,106 (70.33) | 18,634 (49.99) | |||||
| Chemotherapy | 573,306 | 432,081 | 141,225 | 103,947 | 37,278 | |||||
| Yes | 40,210 (7.01) | 27,807 (6.44) | 12,403 (8.78) | 8,000 (7.70) | 4,403 (11.81) | |||||
| No | 533,096 (92.99) | 404,274 (93.56) | 128,822 (91.22) | 95,947 (92.30) | 32,875 (88.19) | |||||
| Surgery | 569,351 | 429,758 | 139,593 | 103,154 | 36,439 | |||||
| Yes | 393,432 (69.10) | 346,820 (80.70) | 46,612 (33.39) | 35,393 (34.31) | 11,219 (30.79) | |||||
| No | 175,919 (30.90) | 82,938 (19.30) | 92,981 (66.61) | 67,761 (65.69) | 25,220 (69.21) | |||||
a
Number of patients for whom data was available.
NRT, no radiation therapy; RT, radiation therapy; EBRT, external beam radiation therapy; EBRT–BRT, combination of external beam with brachytherapy; SPC, second primary cancer; SPRC, second primary rectal cancer.